Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NUVB | US
0.20
9.05%
Healthcare
Biotechnology
30/06/2024
04/10/2024
2.41
2.39
2.41
2.32
Nuvation Bio Inc. a clinical-stage biopharmaceutical company focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868 a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation including oncogenes comprising c-myc; NUV-1156 an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs as well as NUV-1176 a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York New York.
View LessPrice Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
82.5%1 month
68.2%3 months
68.2%6 months
65.4%-
-
3.11
1.13
0.49
2.23
165.60
-
-537.34M
806.82M
806.82M
-
-32.78K
-
-
-88.30
14.52
8.50
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.83
Range1M
0.99
Range3M
1.80
Rel. volume
0.52
Price X volume
2.05M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Applied Therapeutics Inc | APLT | Biotechnology | 7.7 | 884.31M | -8.22% | n/a | 0.30% |
Cronos Group Inc | CRON | Biotechnology | 2.24 | 856.31M | 3.70% | n/a | 0.19% |
iShares $ Corp Bond ETF USD Dist | LQDA | Biotechnology | 10.03 | 846.31M | 0.25% | n/a | 4.70% |
CARGO Therapeutics Inc. Common Stock | CRGX | Biotechnology | 17.77 | 815.72M | -1.44% | n/a | 6.45% |
Adeptus Health Inc | ADPT | Biotechnology | 5.52 | 814.05M | 7.39% | n/a | 93.65% |
Immunome Inc | IMNM | Biotechnology | 13.17 | 790.92M | -2.44% | n/a | 1.09% |
89bio Inc | ETNB | Biotechnology | 7.19 | 772.52M | -0.96% | n/a | 5.31% |
Capricor Therapeutics Inc | CAPR | Biotechnology | 21.65 | 765.05M | 31.05% | n/a | 45.32% |
TNGX | TNGX | Biotechnology | 6.98 | 747.87M | -0.85% | n/a | 15.28% |
Opthea Limited | OPT | Biotechnology | 4.48 | 746.87M | -2.61% | n/a | -264.65% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 2.23 | 0.76 | Expensive |
Ent. to Revenue | 165.60 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.11 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 68.17 | 74.67 | Par |
Debt to Equity | 1.13 | -1.82 | Expensive |
Debt to Assets | 0.49 | 0.26 | Expensive |
Market Cap | 806.82M | 3.73B | Emerging |